Artiva Biotherapeutics (ARTV) Change in Receivables (2023 - 2024)
Artiva Biotherapeutics (ARTV) posted quarterly Change in Receivables of -$569000.0 for Q4 2024, up 48.37% year-over-year from -$383509.5 in Q1 2024, and down 127.6% quarter-over-quarter from -$250000.0 in Q2 2024.
Powered by 
Analysis
Artiva Biotherapeutics (ARTV) Change in Receivables (2023 - 2024) Analysis & Trends
Artiva Biotherapeutics (ARTV) has reported Change in Receivables for 2 consecutive years, with -$569000.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Change in Receivables rose 48.37% year-over-year to -$569000.0; the TTM figure through Mar 2025 stood at -$819000.0 (changed N/A YoY), while the FY2024 annual figure was -$1.0 million, down 302.75% from the prior year.
- Change in Receivables retreated to -$569000.0 in Q4 2024 per ARTV's latest filing, from -$250000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at -$80000.0 in Q3 2023 and bottomed at -$1.1 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Artiva Biotherapeutics | 441.23 Mn | 441.23 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -569,000.00 |
| Jun 30, 2024 | -250,000.00 |
| Mar 31, 2024 | -215,000.00 |
| Dec 31, 2023 | -1.10 Mn |
| Sep 30, 2023 | -80,000.00 |